Original Articles

Evaluation of overall survival and disease-free survival of adjuvant chemotherapy and hormone therapy in patients with breast cancer

Abstract

Abstract : Background: This study evaluated the effect of adjuvant chemotherapy and hormone therapy on overall survival and disease-free survival in patients with breast cancer with hormone receptor-positive, HER2-negative tumor without lymph node involvement. Methods: Breast cancer patients with hormone receptor-positive, HER2-negative, and no lymph node involvement were included in this retrospective cohort study. Patient records were used to collect data on sex, age, time of disease onset, tumor subtype, tumor size, grade, lymphovascular and perineural involvement, ki67, and treatment protocols. Patients were divided into 2 groups: Patients who received both adjuvant chemotherapy and hormonal therapy and patients who received hormonal therapy only. Disease-free survival index (DFS) and overall survival index (OS) were evaluated. Results: Sixty-seven female patients were enrolled in this study. Of them, 68.2% received both adjuvant chemotherapy and hormonal therapy and 31.6% received hormonal therapy only. During follow-up, recurrences occurred in 8 patients. The 3-year and 5-year DFS were 93.4% and 90%, respectively. The 3-year and 5-year DFS were 94% and 92%, respectively, in patients who received both adjuvant chemotherapy and hormonal therapy, and 91% and 85%, respectively, in patients who received hormonal therapy. None of the factors studied affected the 3-year and 5-year DFS. The 3-year and 5-year DFS OS were 98.6% and 96.9%, respectively CONCLUSION: Adjuvant chemotherapy in patients with breast cancer with hormone receptor-positive, HER2-negative, and no lymph node involvement compared with similar patients receiving hormone therapy alone had no significant difference in disease-free survival index and overall survival index. Keywords: breast cancer; disease-free survival index; overall survival index
Uncategorized References
1. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406(6797):747-52 doi: 10.1038/35021093[published Online First: Epub Date]|.
2. Ariazi EA, Taylor JC, Black MA, et al. A New Role for ERα: Silencing via DNA Methylation of Basal, Stem Cell, and EMT Genes. Mol Cancer Res 2017;15(2):152-64 doi: 10.1158/1541-7786.Mcr-16-0283[published Online First: Epub Date]|.
3. Nielsen TO, Parker JS, Leung S, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010;16(21):5222-32 doi: 10.1158/1078-0432.Ccr-10-1282[published Online First: Epub Date]|.
4. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98(19):10869-74 doi: 10.1073/pnas.191367098[published Online First: Epub Date]|.
5. Salari S, Ghadyani M, Karimi M, Mortezazadeh M, Vahedifard F. Immunohistochemical Expression Pattern of MLH1, MSH2, MSH6, and PMS2 in Tumor Specimen of Iranian Gastric Carcinoma Patients. Journal of Gastrointestinal Cancer 2022;53(1):192-96 doi: 10.1007/s12029-020-00566-x[published Online First: Epub Date]|.
6. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22(8):1736-47 doi: 10.1093/annonc/mdr304[published Online First: Epub Date]|.
7. Wöckel A, Festl J, Stüber T, et al. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer. Geburtshilfe Frauenheilkd 2018;78(10):927-48 doi: 10.1055/a-0646-4522[published Online First: Epub Date]|.
8. Parisi F, Razeti MG, Blondeaux E, et al. Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer. Clinical Medicine Insights: Oncology 2020;14:1179554920931816 doi: 10.1177/1179554920931816[published Online First: Epub Date]|.
9. Pellegrino B, Hlavata Z, Migali C, et al. Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression. Mol Diagn Ther 2021;25(4):409-24 doi: 10.1007/s40291-021-00525-7[published Online First: Epub Date]|.
10. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100(14):8418-23 doi: 10.1073/pnas.0932692100[published Online First: Epub Date]|.
11. Phipps AI, Buist DS, Malone KE, et al. Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. Cancer Causes Control 2011;22(3):399-405 doi: 10.1007/s10552-010-9709-0[published Online First: Epub Date]|.
12. Ejlertsen B, Mouridsen HT, Jensen MB, et al. Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer. Cancer 2010;116(9):2081-9 doi: 10.1002/cncr.24969[published Online First: Epub Date]|.
13. Bjelic-Radisic V, Esfandbod M, Alipour S. Pregnancy in Breast Cancer Survivors. In: Alipour S, Omranipour R, eds. Diseases of the Breast during Pregnancy and Lactation. Cham: Springer International Publishing, 2020:165-74.
14. Uchida N, Suda T, Ishiguro K. Effect of chemotherapy for luminal a breast cancer. Yonago Acta Med 2013;56(2):51-6
15. Kwak HY, Chae BJ, Eom YH, et al. Is adjuvant chemotherapy omissible in women with T1-2 stage, node-positive, luminal A type breast cancer? J Chemother 2015;27(5):290-6 doi: 10.1179/1973947815y.0000000015[published Online First: Epub Date]|.
16. Colleoni M, Sun Z, Price KN, et al. Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. J Clin Oncol 2016;34(9):927-35 doi: 10.1200/jco.2015.62.3504[published Online First: Epub Date]|.
17. Adachi Y, Oze I, Sawaki M, et al. Impact of adjuvant endocrine therapy on prognosis in small hormone receptor-positive, HER2-negative early breast cancer. Breast Cancer 2021;28(5):1087-95 doi: 10.1007/s12282-021-01245-w[published Online First: Epub Date]|.
18. Pagani O, Gelber S, Simoncini E, et al. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Res Treat 2009;116(3):491-500 doi: 10.1007/s10549-008-0225-9[published Online First: Epub Date]|.
19. You KY, Zou WL, Ding L, Bi ZF, Yao HR. Large Tumor Size is an Indicator for the Timely Administration of Adjuvant Radiotherapy in Luminal Breast Cancer with Positive Lymph Node. Cancer Manag Res 2021;13:1325-32 doi: 10.2147/cmar.S293470[published Online First: Epub Date]|.
20. Masuda N, Lee S-J, Ohtani S, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. New England Journal of Medicine 2017;376(22):2147-59 doi: 10.1056/NEJMoa1612645[published Online First: Epub Date]|.
21. Li J-J, Shao Z-M. Endocrine therapy as adjuvant or neoadjuvant therapy for breast cancer: selecting the best agents, the timing and duration of treatment. Chinese Clinical Oncology 2016;5(3):40
22. Sharifi A, Kashani M, Salimzadeh A, Ebrahimi M, Savadkouhi MN. Decreased bone mineral density, Vitamin K and Vitamin D in ulcerative colitis patients. Medicina Clínica Práctica 2021;4(4):100276 doi: https://doi.org/10.1016/j.mcpsp.2021.100276[published Online First: Epub Date]|.
23. Chew HK. Adjuvant therapy for breast cancer: who should get what? West J Med 2001;174(4):284-7 doi: 10.1136/ewjm.174.4.284[published Online First: Epub Date]|.
Files
IssueVol 14 No 2 (2022) QRcode
SectionOriginal Articles
DOI https://doi.org/10.18502/bccr.v14i2.14376
Keywords
breast cancer; disease-free survival index; overall survival index
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Roudini K, Mirzania M, Emami SA, Safayi SR, Kamali yazdi E, Zarifi N, Mortezazadeh M, Rafiee S, Mofidi A, Kashani M, Mansouri E sadat, Siahkalmahalleh M, Khajeh Mehrizi A. Evaluation of overall survival and disease-free survival of adjuvant chemotherapy and hormone therapy in patients with breast cancer. Basic Clin Cancer Res. 2023;14(2):87-94.